GSK Acquires Conjugated Vaccine Expertise With GlycoVaxyn Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
The technology could speed the development of prophylactic and therapeutic conjugated vaccines against difficult-to-treat bacterial infections, and the two companies are planning an innovative collaboration that will see GlycoVaxyn retain its autonomy and agility.